Table 2.

Top 20 one-target genes obtained using the IACT framework. SPTLC1/2/3 is a complex of serine palmitoyltransferase constructed by SPTLC1, SPTLC2, and SPTLC3. Other genes each encode for a single enzyme, as shown in the abbreviations section. The symbol (–) denotes that data are unavailable.

Gene	${\mathit{\eta }}_{\mathbf{CV}}{}^{†}$	${\mathit{\eta }}_{\mathbf{DV}}{}^{‡}$	${\mathit{\eta }}_{\mathbf{SE}}{}^{\S }$	N/D ${}^{♭}$	nDrugs ${}^{♮}$	Ave. AE ${}^{♯}$	Pathway ${}^{\mathbf{\P }}$
HMGCR	0.719	0.675	0.637	50/51	20	8.77	Cholesterol Biosynthesis, Statin Pathway, Mevalonate Pathway
MVK	0.719	0.669	0.636	50/51	1	–	Mevalonate Pathway, Regulation of Cholesterol Biosynthesis By SREBP
MVD	0.719	0.669	0.636	48/51	–	–	Mevalonate Pathway, Regulation of Cholesterol Biosynthesis By SREBP
PMVK	0.719	0.669	0.636	23/51	–	–	Mevalonate Pathway, Regulation of Cholesterol Biosynthesis By SREBP
SQLE	0.719	0.672	0.637	3/51	4	6.73	Cholesterol Biosynthesis III, Statin Pathway
FDFT1	0.719	0.674	0.637	8/51	1	–	Cholesterol Biosynthesis III, Statin Pathway
EBP	0.719	0.674	0.637	0/51	1	8.94	Cholesterol Biosynthesis III
LSS	0.719	0.672	0.637	0/51	2	–	Cholesterol Biosynthesis III
NSDHL	0.719	0.674	0.637	0/51	1	–	Cholesterol Biosynthesis III
SPTLC1/2/3	0.719	0.670	0.636	37/51	2	–	Sphingolipid Metabolism
KDSR	0.719	0.670	0.636	6/51	–	–	Sphingolipid Metabolism
CRLS1	0.719	0.669	0.636	38/51	–	–	Glycerophospholipid Biosynthesis
PGS1	0.719	0.448	0.492	50/51	–	–	Glycerophospholipid Biosynthesis
PTDSS1	1.0	0.303	0.477	8/51	1	–	Glycerophospholipid Biosynthesis
ADSL	0.719	0.669	0.636	49/51	–	–	Metabolism of Nucleotides, Purine Metabolism
ADSS2	0.719	0.669	0.636	37/51	3	–	Metabolism of Nucleotides, Purine Metabolism
UMPS	0.719	0.655	0.632	29/51	2	9.82	Metabolism of Nucleotides, Pyrimidine Biosynthesis
DHODH	0.719	0.448	0.492	19/51	26	10.04	Metabolism of Nucleotides, Pyrimidine Biosynthesis
CAD	0.719	0.669	0.636	27/51	3	8.9	Metabolism of Nucleotides, Pyrimidine Biosynthesis
RPIA	0.719	0.675	0.637	6/51	1	–	Pentose Phosphate Pathway

${}^{†}$ Cell viability grade as evaluated from cancer cell treatment and the perturbations of normal cells due to treatment; ‡ Metabolic deviation grade indicating the perturbance of the cellular flux patterns as measured by dissimilarity to the cancer template and similarity to the basal template; ${}^{\S }$ Side effect grade. A higher ${\eta }_{SE}$ indicates fewer predicted side effects; ${}^{♭}$ The cell death number (N) divided by the total number of colon cancer cells (D) used for the test from DepMap; ${}^{♮}$ The number of drugs retrieved from DrugBank that modulate each gene; ${}^{♯}$ Average grade of adverse events for drugs acting on an identified gene; ${}^{\P }$ Accessed from GeneCards.